Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITHIODOTE vs SODIUM THIOSULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.
Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.
FDA-approved for the treatment of acute cyanide poisoning,Off-label: May be used for cyanide poisoning due to smoke inhalation or certain chemical exposures
FDA-approved: Acute cyanide poisoning (in combination with sodium nitrite),Off-label: Reduction of nephrotoxicity from cisplatin chemotherapy,Off-label: Calciphylaxis (calcium uremic arteriolopathy),Off-label: Treatment of extravasation of vesicant drugs
NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.
12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.
Terminal elimination half-life: 2.5–3 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: 0.65 hours (IV in cyanide poisoning); context: rapid redistribution and excretion, requiring repeated doses.
Sodium nitrite is partially metabolized to nitric oxide and other metabolites; sodium thiosulfate is primarily excreted unchanged in urine, with minor metabolism by rhodanese in the liver and kidneys.
Sodium thiosulfate is metabolized via the enzyme rhodanese (in liver and other tissues) to thiocyanate, which is then excreted renally. It also undergoes oxidation to sulfate.
Primarily renal as unchanged drug and metabolites; biliary/fecal excretion minimal (<5%).
Renal: >90% unchanged; minor biliary/fecal.
Approximately 90% bound to albumin.
<5%; primarily albumin.
0.35 L/kg, indicating moderate tissue distribution.
0.2-0.3 L/kg; indicates primarily extracellular distribution.
Oral: 60–80% (first-pass metabolism); IV: 100%.
Oral: approximately 0% (poorly absorbed, degraded in stomach); IV: 100%.
No dose adjustment required for mild-moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), consider reducing sodium thiosulfate dose by 50% and monitoring serum thiocyanate levels.
No dose adjustment required for GFR >30 m L/min; for GFR ≤30 m L/min, consider reducing dose by 50% or extending interval to every 12 hours due to possible thiosulfate accumulation.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-severe (Child-Pugh B/C), use with caution; consider reducing sodium nitrite dose by 50% due to increased methemoglobinemia risk.
No specific recommendations for Child-Pugh; use with caution in severe hepatic impairment due to potential metabolic and elimination effects.
Children: Sodium nitrite 0.15-0.33 m L/kg of 3% solution (4.5-10 mg/kg) IV push over 2 minutes, followed by sodium thiosulfate 1.65 m L/kg of 25% solution (412.5 mg/kg) IV push over 10 minutes. Repeat half doses if symptoms persist.
For cyanide poisoning: 412.5 mg/kg (1.65 m L/kg of 25% solution) intravenously over 10 minutes; for methemoglobinemia: 1 mg/kg intravenously over 10 minutes.
Geriatric patients: Use weight-based dosing (same as adult). Start with lower doses (e.g., sodium nitrite 5 mg/kg) due to increased risk of hypotension and methemoglobinemia. Monitor vital signs frequently.
No specific dose adjustments; monitor renal function and volume status due to sodium load and potential reduced clearance.
None
None.
May cause severe hypotension, especially in children,Risk of methemoglobinemia with excessive sodium nitrite,Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as hemolysis may occur,Monitor methemoglobin levels, blood pressure, and oxygen saturation during therapy,Sodium thiosulfate may cause hypocalcemia in high doses
Hypotension and increased anion gap metabolic acidosis (especially with high doses or rapid infusion),Hypocalcemia due to calcium chelation; monitor calcium levels,Thiocyanate accumulation, particularly in renal impairment; can lead to toxicity (e.g., nausea, disorientation, psychosis, muscle cramps),Hydration status should be monitored to avoid volume overload,Hypersensitivity reactions may occur
Hypersensitivity to any component of the product,Children under 6 months of age (relative contraindication due to increased risk of hypotension and methemoglobinemia)
Known hypersensitivity to sodium thiosulfate or any component,Relative: Severe renal impairment (risk of thiocyanate toxicity)
No known food interactions. Avoid alcohol as it may impair liver function and worsen acidosis.
No known food interactions. Maintain adequate hydration unless contraindicated by renal status.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemoglobinemia and hemolytic anemia due to methylene blue component; avoid near term due to risk of neonatal methemoglobinemia.
Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide poisoning during pregnancy when benefit outweighs risk.
No human data; methylene blue is excreted in breast milk with an M/P ratio of approximately 0.7. Potential for infant methemoglobinemia; caution advised. Consider withholding breastfeeding for 4-6 hours after maternal dose.
Sodium thiosulfate is excreted into breast milk in small amounts; M/P ratio is not established. It is considered compatible with breastfeeding, but caution is advised due to limited data.
Standard dosing (1 mg/kg IV) used in pregnancy; consider lower dose (0.5-1 mg/kg) if severe anemia or G6PD deficiency. No routine dose adjustment, but monitor for maternal hypotension and fetal bradycardia.
No dosage adjustment is recommended for pregnancy. Pharmacokinetic changes in pregnancy are not well studied; standard weight-based dosing for cyanide poisoning should be used.
NITHIODOTE (sodium nitrite and sodium thiosulfate) is indicated for acute cyanide poisoning. Administer intravenously as soon as possible after exposure. Monitor methemoglobin levels; do not exceed 20% methemoglobinemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Sodium nitrite induces methemoglobinemia which can impair oxygen delivery; ensure adequate ventilation. Sodium thiosulfate is generally safer and can be given separately.
Sodium thiosulfate is used as an antidote for cyanide poisoning and for calciphylaxis. In cyanide poisoning, administer IV with sodium nitrite; monitor for hypotension and methemoglobinemia. For calciphylaxis, use after hemodialysis to prevent hypernatremia. Can cause prolonged QT interval, so monitor ECG. Do not mix with other drugs in IV line; incompatible with cisplatin.
This medication is only used in hospital settings for cyanide poisoning.,It is given through an IV line as soon as possible after exposure.,You may experience symptoms of low oxygen such as headache, confusion, or blue skin due to methemoglobin formation.,Tell your doctor if you have a history of G6PD deficiency, anemia, or breathing problems.,Follow-up blood tests will be needed to monitor your oxygen levels and blood counts.
This medication is given intravenously to treat cyanide poisoning or a skin condition called calciphylaxis.,You may experience side effects such as nausea, vomiting, headache, or a metallic taste.,Your blood pressure, heart rhythm, and blood levels will be monitored during treatment.,Tell your doctor if you have heart problems, kidney disease, or low sodium levels.,Do not drink alcohol while on this medication.
No interactions on record
No interactions on record
Common clinical questions about NITHIODOTE vs SODIUM THIOSULFATE, answered by our medical review team.
NITHIODOTE is a Cyanide Antidote that works by Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.. SODIUM THIOSULFATE is a Cyanide Antidote that works by Sodium thiosulfate acts as a cyanide antidote by providing a sulfur donor for the enzyme rhodanese, which converts cyanide to the less toxic thiocyanate. It also acts as a reducing agent and chelator of calcium, forming soluble calcium thiosulfate complexes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITHIODOTE and SODIUM THIOSULFATE depend on the specific clinical indication. These are both Cyanide Antidote agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITHIODOTE is: NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.. The standard adult dose of SODIUM THIOSULFATE is: 12.5 g (50 m L of 25% solution) intravenously over 10 minutes for cyanide poisoning; for cisplatin otoprotection: 9 g/m² intravenously over 15 minutes after cisplatin.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITHIODOTE and SODIUM THIOSULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITHIODOTE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemogl. SODIUM THIOSULFATE is classified as Category C. Sodium thiosulfate is not known to be teratogenic. No specific fetal risks have been identified; however, data in pregnant women are limited. It is used as an antidote for cyanide . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.